Inclusion Criteria:  All participants must have been treated with a fixed dose combination of fluticasone propionate/salmeterol in one of two doses in stable dose alone or with additional controllers at label approved dosage (allowed only: LTRA, LAMA, Theophylline or its derivatives). Participants completing the Treatment period and Follow-up period of study CSJ117A12201C and continuing with study CCSJ117A12201E1 must have completed the Treatment period of CSJ117A12201C (i.e. did not discontinue blinded study treatment prematurely) and Follow-up period of study CSJ117A12201C.  Exclusion Criteria:  Participants who were enrolled into prior study CSJ117A12201C and developed a significant and/or permanent health condition during the prior study. Participants who experienced a serious and drug-related AE in the prior study CSJ117A12201C. Participants receiving any prohibited medications. Participants with a history or current diagnosis of ECG abnormalities. Pregnant or nursing (lactating) women.